ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Director, US Commercial Enablement at Dyne Therapeutics - ApplyBlast

Director, US Commercial Enablement

Dyne Therapeutics

4 months ago

4.1 on Glassdoor

Waltham, MA

Onsite

Full Time

Director

1 applicant

View Job Listing

Apply to 100+ jobs

About this role

The Director of US Commercial Enablement at Dyne Therapeutics drives strategic initiatives to support business growth and launch readiness for neuromuscular disease therapeutics. This role establishes field enablement infrastructure, including incentive compensation programs, CRM platforms, and business intelligence tools, while ensuring alignment across cross-functional stakeholders. The position focuses on enhancing field effectiveness, building scalable processes, and promoting operational excellence with a patient-first mindset.

Responsibilities

Design and administer incentive compensation and bonus programs across commercial teams
Optimize CRM platforms and translate field needs into system enhancements
Own business intelligence reporting tools and ensure data accuracy
Design and implement fleet programs aligned with business needs
Drive cross-functional planning to support commercial launch and execution

Skills

Qualifications

Bachelor's DegreeAdvanced Degree Preferred

About Dyne Therapeutics

dyne-tx.com

Headquarters

Waltham, Massachusetts, United States

Company Size

51-200 employees

Founded

2018

View Profile

Dyne Therapeutics is a biotechnology company developing nucleic acid–based therapies for genetically driven neuromuscular diseases. Leveraging its proprietary FORCE™ platform, Dyne aims to address the root cause of disease and deliver functional improvement for people living with conditions such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). The company advances a pipeline of therapeutics from discovery through clinical development with the mission of transforming the lives of patients with rare neuromuscular diseases.